Literature DB >> 427816

Estrogen and progesterone receptors in human breast cancer with concomitant assay of plasma 17beta-estradiol, progesterone, and prolactin levels.

R Nagai, M Kataoka, S Kobayashi, K Ishihara, N Tobioka, K Nakashima, M Naruse, K Saito, S Sakuma.   

Abstract

The specific estrogen receptor in the cytosol of human breast cancer tissue was assayed in 217 primary cases. The specific progesterone receptor was also assayed in 48 cases as evidence of estrogen action on the tissue. Both receptors were positive in 45.8% of all cases. Plasma 17beta-estradiol and progesterone were assayed concomitantly with these steroid receptors. The higher hormone levels were found in the cases with fewer receptor binding sites. The relationship between 17beta-estradiol levels in tumor cytosol and the number of binding sites was more clearly observed. Plasma prolactin levels, however, showed no correlation with the number of receptor binding sites or the plasma levels of sex steroids. None of these assayed substances had a clear correlation with the histological type of tumor or the clinical stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 427816

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients.

Authors:  H J Helin; J J Isola; M J Helle; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

2.  NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas.

Authors:  A O Stemmer-Rachamimov; T Wiederhold; G P Nielsen; M James; D Pinney-Michalowski; J E Roy; W A Cohen; V Ramesh; D N Louis
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

Review 3.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

4.  Cytosol and nuclear estrogen receptors (occupied and unoccupied sites) and progesterone receptors in human breast cancer.

Authors:  C Sumida; H Magdelenat; J R Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

5.  Estrogen receptor status of breast cancer in Ontario.

Authors:  G E McKeown-Eyssen; I Rogers-Melamed; E A Clarke
Journal:  CMAJ       Date:  1985-11-15       Impact factor: 8.262

6.  Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.

Authors:  Piiha-Lotta Jerevall; Agneta Jansson; Tommy Fornander; Lambert Skoog; Bo Nordenskjöld; Olle Stål
Journal:  Breast Cancer Res       Date:  2010-07-22       Impact factor: 6.466

7.  Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast.

Authors:  K S McCarty; J S Silva; E B Cox; G S Leight; S A Wells; K S McCarty
Journal:  Ann Surg       Date:  1983-02       Impact factor: 12.969

Review 8.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

9.  Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle.

Authors:  D A Weimer; W L Donegan
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

Review 10.  Reproductive history and breast cancer risk.

Authors:  Shunzo Kobayashi; Hiroshi Sugiura; Yoshiaki Ando; Norio Shiraki; Takeshi Yanagi; Hiroko Yamashita; Tatsuya Toyama
Journal:  Breast Cancer       Date:  2012-06-19       Impact factor: 4.239

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.